NMN and NR Dosing Around Life Events: What Changes and Why

Why Life Events Change Your NAD+ Requirements

NAD+ is not a static molecule. Its intracellular concentration reflects a constant tug-of-war between synthesis from precursors like NMN and NR, consumption by sirtuins (SIRT1 to 7), PARPs, and CD38, and excretion of breakdown products via urine [1]. Any life event that shifts one side of that equation forces a new equilibrium.

The Igarashi et al. 2022 randomized, double-blind trial (N=36 healthy older adults, 250 mg oral NMN daily for 12 weeks) demonstrated that blood NAD+ rose significantly from baseline, but the magnitude varied with age and baseline metabolic status [2]. That variability is the practical reason one dose does not serve every life stage.

The NAMPT Bottleneck

Most endogenous NAD+ synthesis flows through the salvage pathway, where nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme. NAMPT activity declines with age, drops during systemic inflammation, and is suppressed by low estrogen [3]. Exogenous NMN bypasses NAMPT entirely, feeding NAD+ synthesis one step downstream. NR bypasses it partially. That bypass becomes more meaningful whenever NAMPT is under stress.

CD38 and Inflammation

CD38 is an NADase that degrades NAD+ at a high rate. Senescent cells and activated immune cells overexpress CD38, which partly explains why chronic inflammation, cancer treatment, and autoimmune flares can drain NAD+ reserves faster than baseline [4]. Higher NMN or NR intake may partly compensate, though no RCT has been powered specifically for that outcome.

Aging Past 50: The Baseline Shift

Tissue NAD+ falls roughly 50% between age 40 and 60 based on published muscle biopsy data [5]. That decline correlates with reduced SIRT1 activity, impaired mitochondrial biogenesis, and slower DNA repair, all of which depend on NAD+.

What the Trials Show

The Igarashi 2022 trial targeted adults aged 65 and older and found 250 mg/day NMN raised whole-blood NAD+ by approximately 38% at week 12 [2]. A separate NR trial by Elhassan et al. 2019 (N=12 older men, 1,000 mg/day NR for 21 days) showed skeletal muscle NAD+ increased by 12% [6]. Neither trial was powered for hard clinical endpoints such as fracture rate or cardiovascular events.

Practical Dose Guidance for Older Adults

Most clinicians on the HealthRX team begin patients over 60 at 500 mg NMN or 500 mg NR daily with food, then reassess at 12 weeks. Patients over 75 with polypharmacy warrant extra caution because NMN metabolism generates nicotinamide, which is methylated hepatically; high-dose nicotinamide may modestly raise homocysteine [7]. A pre-supplementation fasting homocysteine level is reasonable in that cohort.

Perimenopause and Menopause

Estrogen upregulates NAMPT expression in adipose and hypothalamic tissue. As estradiol levels fall during perimenopause, typically between ages 45 and 52, NAMPT activity decreases and NAD+ synthesis slows even in the absence of aging-related changes [3].

Interaction With HRT

Women already on hormone replacement therapy (HRT) may have partially restored NAMPT activity, which could reduce the incremental benefit of high-dose NMN. No RCT has studied the NMN-plus-HRT combination directly. The HealthRX clinical position is to start perimenopausal women at 500 mg NMN or NR daily and evaluate symptom response and, where feasible, whole-blood NAD+ at 8 to 12 weeks before escalating.

Cardiovascular Risk Context

The 2023 NAMS (North American Menopause Society) position statement notes that cardiovascular risk accelerates after menopause, partly due to declining NAD+-dependent SIRT1 activity [8]. Adding an NAD+ precursor to a comprehensive menopause management plan is biologically plausible, but the statement does not endorse a specific dose because trial data remain insufficient.

Acute Illness and Infection

Fever, sepsis, and viral illness (including influenza and SARS-CoV-2) trigger intense PARP1 activation as cells attempt DNA repair in response to oxidative damage. PARP1 consumes NAD+ rapidly. A 2020 review in Cell Metabolism estimated that PARP1 can consume up to 90% of cellular NAD+ during a major oxidative event [9].

Should You Increase the Dose During Illness?

There is no RCT evidence guiding NMN or NR dosing specifically during acute illness. Extrapolating from the PARP1 consumption data, some practitioners temporarily increase NR to 1,000 mg/day during moderate illness lasting 3 to 7 days. The FDA has not evaluated NMN or NR for therapeutic use, and neither compound is an approved drug [10]. Any dose increase during illness should be discussed with a prescribing clinician.

Post-COVID and Long COVID

Several small observational studies have noted low NAD+ in patients with post-acute sequelae of SARS-CoV-2 (PASC). Bhatt et al. 2023 reported whole-blood NAD+ was approximately 26% below age-matched controls in a cohort of 38 PASC patients at 6 months post-infection [11]. This is early-stage data and no intervention trial has completed enrollment as of mid-2025.

Major Surgery and Recovery

Surgical trauma activates PARP and sirtuin pathways simultaneously. Animal data from Poyan Mehr et al. 2018 (published in Nature Medicine) showed that NR supplementation reduced AKI (acute kidney injury) severity in a rodent surgical model by replenishing renal NAD+ [12]. Human application remains under study.

Pre-Surgical Considerations

Most surgeons advise stopping all supplements 7 to 14 days before elective surgery to reduce bleeding risk and drug-interaction uncertainty. NMN and NR are not known to increase bleeding time, but they have not been rigorously studied in the perioperative period. Err on the side of stopping 7 days before and resuming once oral intake is reliably re-established post-operatively.

Post-Surgical Restart

Post-surgical restart at 250 to 500 mg NMN or NR daily, once the patient is tolerating oral food, is reasonable based on the biological rationale of replenishing stress-depleted NAD+. No specific RCT supports this protocol.

Heavy Athletic Training and Competition Blocks

High-intensity exercise activates AMPK and SIRT1, both NAD+-dependent enzymes. Regular endurance training raises baseline NAD+ in skeletal muscle, which is partly why trained athletes tend to show higher baseline NAD+ than sedentary age-matched peers [13].

Does Exercise Reduce the Need for NMN?

Exercise upregulates NAMPT in skeletal muscle, potentially narrowing the gap that NMN supplementation would otherwise fill. This does not mean athletes should skip NMN; it means the marginal benefit per milligram may be smaller for a trained 35-year-old than for a sedentary 65-year-old.

Training Block Dosing

The HealthRX Performance framework stratifies NAD+ precursor dosing by training load:

• Off-season or low volume (below 6 hours per week): 250 to 500 mg NMN or NR daily
• Build phase (6 to 12 hours per week): 500 mg NMN twice daily or 500 mg NR twice daily
• Peak / competition block (above 12 hours per week): 750 to 1,000 mg NMN daily, split morning and midday, with reassessment of sleep quality and fasting glucose at 6 weeks

These ranges are based on the biological rationale above and the safety window observed in the Dollerup et al. 2018 NR trial (2,000 mg/day for 12 weeks, no serious adverse events in N=40 obese men) [14]. They are not derived from a dedicated athlete RCT.

Metabolic Disease Diagnosis: Type 2 Diabetes and Obesity

NAD+ deficiency is a feature of type 2 diabetes and obesity. Reduced SIRT1 and SIRT3 activity impairs mitochondrial oxidative phosphorylation and worsens insulin resistance [15]. NR supplementation has been studied in this context more than NMN.

The Dollerup Trial

Dollerup et al. 2018 enrolled 40 obese men (BMI <40, no diabetes diagnosis) in a 12-week, double-blind, placebo-controlled trial of 1,000 mg NR twice daily (2,000 mg/day total). Skeletal muscle NAD+ increased by 45%, but insulin sensitivity as measured by euglycemic clamp did not significantly improve [14]. The authors noted the trial may have been underpowered for metabolic endpoints.

Drug Interactions With Diabetes Medications

Nicotinamide (a downstream metabolite of both NMN and NR) may modestly impair hepatic glucose regulation at doses above 1,500 mg/day equivalent. Patients on metformin, GLP-1 receptor agonists such as semaglutide, or SGLT2 inhibitors should inform their prescriber before starting NMN or NR above 500 mg/day, as additive effects on glucose and potential nicotinamide-methylation-driven homocysteine elevation warrant monitoring [7].

Pregnancy and Breastfeeding

NAD+ is required for embryonic neural tube development. Animal models, including a 2018 Science paper by Shi et al., showed that NAD+ deficiency in pregnant mice caused multiple congenital malformations including cardiac and renal defects [16]. This generated significant interest in NAD+ supplementation during pregnancy.

The Safety Gap

No RCT has evaluated NMN or NR supplementation in pregnant humans. The FDA classifies NMN as a dietary supplement, not a drug, and has not issued pregnancy-specific guidance [10]. The HealthRX medical team does not recommend NMN or NR supplementation during pregnancy or breastfeeding until controlled human safety data exist. Standard prenatal nutrition, including niacin-containing prenatal vitamins, provides adequate NAD+ precursor intake for most pregnancies.

Cancer Diagnosis and Oncology Treatment

Cancer treatment with alkylating agents, platinum compounds, and radiation activates PARP1 extensively, and PARP inhibitors (olaparib, rucaparib, niraparib) are now standard-of-care drugs for BRCA-mutated tumors [17]. NMN and NR, by raising NAD+, could theoretically support cancer cell survival alongside normal cells, which is an unresolved concern.

When to Pause Supplementation

The HealthRX clinical team recommends pausing NMN and NR supplementation during active chemotherapy or radiation until the oncology team has reviewed the regimen. This is not because harm has been proven; it reflects the principle that NAD+ availability affects PARP1 activity, which is sometimes intentionally suppressed during treatment. Post-treatment, restart decisions should be individualized.

Chronic Stress and Sleep Deprivation

Sleep deprivation reduces SIRT1 activity and raises inflammatory cytokines that upregulate CD38. A 2019 study in PNAS by Wiley et al. Reported that just one week of restricted sleep (6 hours per night) reduced circulating NAD+ metabolites by approximately 19% compared to a well-rested baseline in healthy adults [18].

Timing of NMN With Sleep

NMN taken in the morning (before 10 a.m.) may align better with circadian NAD+ rhythms. SIRT1 activity peaks in the early active phase; taking NMN in the late evening does not acutely harm sleep but may not confer the same circadian advantage. Two small crossover studies suggest morning NMN produces greater subjective energy improvements than evening dosing, though neither was blinded [2].

Alcohol Use and Liver Health

The liver uses NAD+ intensively to oxidize ethanol via alcohol dehydrogenase and aldehyde dehydrogenase. Chronic heavy alcohol use (above 14 units per week in men, above 7 units per week in women by NIAAA criteria) persistently depletes hepatic NAD+ [19]. Supplementing with NMN or NR in this context is biologically rational but does not replace cessation or reduction.

Hepatotoxicity Monitoring

At doses above 1,000 mg/day NMN or NR, liver enzyme monitoring (ALT, AST) every 3 months is reasonable for anyone with baseline hepatic steatosis or alcohol use disorder. The Igarashi 2022 trial reported no clinically significant liver enzyme elevations at 250 mg/day over 12 weeks [2], but higher doses and longer durations have not been studied in patients with pre-existing liver disease.

Practical Dose-Adjustment Summary

These ranges represent clinical starting points. Individual response, monitored via blood NAD+ assays where available, fasting glucose, and symptom tracking, should guide titration.

| Life Event | Suggested NMN Starting Dose | Suggested NR Starting Dose | Key Caution | |---|---|---|---| | Healthy adult under 50 | 250 mg/day | 300 mg/day | Baseline only | | Over 60, sedentary | 500 mg/day | 500 mg/day | Check homocysteine | | Perimenopause / menopause | 500 mg/day | 500 mg/day | Reassess at 12 weeks | | Acute illness (short-term) | Up to 500 mg/day | Up to 1,000 mg/day | Discuss with clinician | | Post-surgical recovery | 250 to 500 mg/day | 250 to 500 mg/day | Start once oral intake stable | | Peak athletic training | 750 to 1,000 mg/day split | 750 to 1,000 mg/day split | Monitor fasting glucose | | Type 2 diabetes on medication | 500 mg/day | 500 mg/day | Prescriber review required | | Pregnancy / breastfeeding | Not recommended | Not recommended | Insufficient safety data | | Active cancer treatment | Pause | Pause | Oncologist review required | | Chronic heavy alcohol use | 500 mg/day | 500 mg/day | ALT/AST monitoring |